22 December 2024

Tag: drug delivery systems

Cybin (CYBN.E) new tryptamine patent improves outcome quality

Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…

24 May 2021
Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights

Mountain Valley MD Holdings (MVMD.C) filed a cancer patent and is moving forward with preclinical trials with third party cancer research organizations (CROs) in triple-negative breast cancer, metastatic melanoma and lung carcinoma, according to a press release. The patent is called Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies, and involves solubilized ivermectin (also…

5 May 2021
Xphyto (XPHY.C) bulks up executive team as Covid-19 ravages Europe

The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.

23 April 2021
That was quick! Xphyto (XPHY.C) orders 9,600 Covid-19 PCR tests – stock up 67% year-to-date

“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting viral RNA, which will be present in the body before symptoms of the disease are present,” the tests give a powerful early warning system.

25 February 2021
Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test

The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.

23 February 2021
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine

Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.

29 January 2021
Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver

On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies.

9 December 2020
Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms

Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.

4 November 2020
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets

Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.

23 September 2020
Xphyto (XPHY.C) updates shareholders on rapid COVID-19 (SARS-CoV-2) screening test

Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early pre-symptomatic and asymptomatic stages of infection

9 September 2020